Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management
Joaquim Bellmunt, Begoña P. Valderrama, Javier Puente, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 174, pp. 103683-103683
Open Access | Times Cited: 19

Showing 19 citing articles:

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
Matthew D. Galsky, J. Alfred Witjes, Jürgen E. Gschwend, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 19
Associations of TACSTD2/TROP2 and NECTIN‐4/NECTIN‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts
Veronika Bahlinger, Annalena Branz, Pamela L. Strissel, et al.
Histopathology (2024) Vol. 84, Iss. 5, pp. 863-876
Open Access | Times Cited: 16
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
Aristotelis Bamias, Ian D. Davis, Matthew D. Galsky, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. 46-61
Closed Access | Times Cited: 21
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
Andrea Necchi, Damien Pouessel, Raya Leibowitz‐Amit, et al.
Annals of Oncology (2023) Vol. 35, Iss. 2, pp. 200-210
Open Access | Times Cited: 14
Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy
Xiangyun You, Chunming Zhu, Puguang Yu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116152-116152
Open Access | Times Cited: 3
Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions
Vicenç Ruiz de Porras, Juan Carlos Pardo, Olatz Etxániz, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 178, pp. 103795-103795
Closed Access | Times Cited: 14
Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
Rui Yang, Wengang Zhang, Xiaoling Shang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 12
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies
Mansoor N. Saleh, Minal Barve, Vivek Subbiah, et al.
ESMO Open (2024) Vol. 9, Iss. 7, pp. 103625-103625
Open Access | Times Cited: 2
Impact of intra‐tumoral immunity on predicting response and survival after neoadjuvant cisplatin‐based chemotherapy in patients with muscle invasive bladder cancer
Alberto Mendoza, Jane Choe, Daria M. Kessler, et al.
Cancer Medicine (2024) Vol. 13, Iss. 15
Open Access | Times Cited: 2
Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients
Thomas Gerald, Vitaly Margulis, Xiaosong Meng, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 41, Iss. 3, pp. 148.e17-148.e24
Closed Access | Times Cited: 6
A narrative review of peripheral blood parameters for urothelial carcinoma treated with systemic antitumor drugs
Takashi Nagai, Taku Naiki, Yosuke Sugiyama, et al.
Translational Andrology and Urology (2023) Vol. 12, Iss. 5, pp. 790-801
Open Access | Times Cited: 4
Prognostic value of pretreatment serum albumin−globulin ratio in urothelial carcinoma: A systematic review and meta-analysis
Zhongyou Xia, Xueqin Fu, Jinze Li, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 7
E-learning pills on immunotherapy in urothelial carcinoma: The E-PIMUC program for continuing medical education
Olga Bustos Romero, Clara Madrid, Juan Carlos Pardo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab
Alicia K. Morgans, Guru P. Sonpavde, Vanessa Shih, et al.
Clinical Genitourinary Cancer (2024) Vol. 23, Iss. 1, pp. 102270-102270
Open Access | Times Cited: 1
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Daniel P. Petrylak, Bernhard J. Eigl, Saby George, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 1, pp. 63-73
Open Access | Times Cited: 2
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Miguel Ángel Climent, Carlos Álvarez-Fernández, Rafael Morales, et al.
Clinical & Translational Oncology (2023) Vol. 26, Iss. 6, pp. 1532-1538
Open Access | Times Cited: 2
Expression of HER2 in urothelial carcinoma and its significance
Yao Chang, Delong Zhao, Zicheng Wang, et al.
Current Urology (2024) Vol. 19, Iss. 3, pp. 201-207
Open Access
Aspectos prácticos sobre la determinación de PD-L1 en el tratamiento de carcinoma urotelial. Consenso del grupo de uropatología de la SEAP
Antonio López-Beltrán, Pilar González‐Peramato, Julián Sanz‐Ortega, et al.
Revista Española de Patología (2023) Vol. 56, Iss. 4, pp. 261-270
Closed Access
Clinicopathological and prognostic significance of Ephrin A3 in bladder urothelial carcinoma
Yifan Wang, Yuning Hu, Ze-Fan Shen, et al.
Oncology Letters (2023) Vol. 26, Iss. 6
Open Access
Page 1

Scroll to top